
Enanta Pharmaceuticals Inc (ENTA)
NASDAQ
Fin d'année 30 Septembre 2024 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Return on Assets (%) | 5.826 | 19.425 | 10.261 | -7.412 | -17.082 | -29.908 | -31.949 | -27.665 |
Return on Equity (%) | 6.197 | 20.696 | 10.835 | -7.879 | -18.478 | -33.785 | -49.739 | -67.166 |
Return on Invested Capital (%) | 6.801 | 22.771 | 9.962 | -10.598 | -22.745 | -42.725 | -56.084 | -71.117 |
Operating Margin (%) | 26.248 | 45.068 | 22.202 | -28.593 | -110.822 | -141.815 | -158.89 | -157.977 |
Net Profit Margin (%) | 17.225 | 34.824 | 22.604 | -29.531 | -81.377 | -141.313 | -168.951 | -171.575 |
Book Value Per Share | 15.778 | 20.298 | 23.473 | 22.692 | 19.737 | 15.508 | 10.294 | 6.08 |
Earnings Per Share | 0.926 | 3.71 | 2.354 | -1.801 | -3.903 | -5.876 | -6.356 | -5.477 |
Cash Per Share | 3.435 | 3.295 | 2.6 | 4.34 | 2.827 | 2.123 | 4.055 | 1.757 |
Working Capital Per Share | 11.341 | 18.786 | 19.248 | 20.555 | 13.976 | 13.605 | 17.098 | 11.437 |
Operating Profit Per Share | 5.377 | 10.654 | 10.415 | 6.1 | 4.797 | 4.158 | 3.762 | 3.192 |
EBIT Per Share | 1.409 | 4.801 | 2.312 | -1.744 | -5.316 | -5.897 | -6.222 | -5.559 |
EBITDA Per Share | 1.409 | 4.801 | 2.312 | -1.744 | -5.316 | -5.897 | -6.222 | -5.559 |
Free Cash Flow Per Share | 0.946 | 3.734 | 2.464 | -1.911 | -4.031 | -5.917 | -6.038 | -4.74 |
Fin d'année 30 Septembre 2024 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Actions en circulation | 19,12M | 19,4M | 19,7M | 20,08M | 20,24M | N/A | N/A | N/A |
Fin d'année 30 Septembre 2024 | Mar 2023 | Juin 2023 | Sept 2023 | Déc 2023 | Mar 2024 | Juin 2024 | Sept 2024 | Déc 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Actions en circulation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Assets (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Equity (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Invested Capital (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Margin (%) | N/A | N/A | N/A | -169.905 | N/A | N/A | N/A | -122.319 |
Net Profit Margin (%) | N/A | N/A | N/A | -185.564 | N/A | N/A | N/A | -131.435 |
Sales Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Earnings Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Working Capital Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBITDA Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Free Cash Flow Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Capitalisation boursière | 90,88M |
Ratio cours/bénéfice | -0,86 |
Ratio prix/ventes | 1,47 |
Ratio prix/liquidités | 2,68 |
Ratio prix/valeur comptable | 0,77 |
Rendement de dividende | - |
Actions en circulation | 21,33M |
Volume moyen (1 semaine) | 378,84k |
Volume moyen (1 mois) | 250,47k |
Variation sur 52 semaines | -71,94% |
Plus haut sur 52 semaines | 17,235 |
Plus bas sur 52 semaines | 4,09 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales